Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
Ronald ChowDavid G WarrRudolph M NavariMay TsaoMarko PopovicLeonard ChiuMilica MilakovicHenry LamCarlo DeAngelisPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018)
Palonosetron seems to be more efficacious and safe than other 5-HT3RAs-statistically superior in 10 of 19 endpoints. It is, however, only clinically significant in one endpoint and approached clinically significant difference in another two endpoints. Within the limits of this meta-analysis, our results indicate that palonosetron may not be as superior in efficacy and safety as reported in a previous meta-analysis, and supports the recent MASCC/ESMO, ASCO, and NCCN guidelines in not generally indicating palonosetron as the 5-HT3RA of choice.